Correction to: Signal Transduction and Targeted Therapy https://doi.org/10.1038/s41392-025-02445-y, published online 16 October 2025
After online publication of the article1, the authors noticed one inadvertent mistake in Acknowledgements part that needs to be corrected. The correct grant number for the “National High Level Hospital Clinical Research Funding” should be “2022-CICAMS-80102022503”.
The key findings of the article are not affected by these corrections.
The original version of this article is corrected.
Reference
Yang, Y. et al. Circulating tumor DNA refines consolidation immunotherapy for limited-stage small cell lung cancer patients. Sig. Transduct. Target. Ther 10, 347 (2025).
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Yang, Y., Wu, Y., Zhao, J. et al. Correction: Circulating tumor DNA refines consolidation immunotherapy for limited-stage small cell lung cancer patients. Sig Transduct Target Ther 11, 36 (2026). https://doi.org/10.1038/s41392-025-02526-y
Published:
Version of record:
DOI: https://doi.org/10.1038/s41392-025-02526-y
